How to Help Your Patients Save Money on Venofer: A Provider's Guide to Savings Programs

For many CKD patients, iron deficiency anemia is not only a medical challenge — it's a financial one. Venofer (iron sucrose injection) is a specialty IV medication that is expensive when uninsured, and even insured patients may face significant out-of-pocket costs depending on their coverage type, setting of care, and payer policies. As a provider, understanding the available savings mechanisms is an important part of supporting your patients' overall treatment success.

This guide is designed for nephrologists, nephrology nurse practitioners and PAs, infusion center staff, and practice managers. It covers the most important savings pathways for Venofer, from manufacturer patient assistance to Medicare billing optimization and formulary cost management.

Understanding How Venofer Is Billed

Venofer is billed as a drug-administered-in-office (J code: J1756 for iron sucrose injection). Because it is an infused medication, it is billed under the patient's medical benefit — not their pharmacy drug benefit (Part D). This distinction matters because:

Patient cost-sharing is determined by their medical deductible and coinsurance — not a fixed copay tier

The setting of care (office vs. hospital outpatient vs. dialysis center) significantly affects reimbursement rates and patient out-of-pocket costs

Patients receiving care in a hospital outpatient setting typically face higher out-of-pocket costs than in a physician office, due to facility fee differences

Medicare Part B: Coverage and Cost Sharing

For Medicare patients, Venofer is covered under Part B. Coverage details:

ESRD/Hemodialysis patients: Venofer is explicitly covered as part of the ESRD bundled payment. Since October 2011, iron sucrose is bundled into the ESRD PPS (Prospective Payment System). Dialysis facilities receive a bundled payment that includes iron administration — this means the facility is reimbursed for Venofer as part of the overall dialysis payment, and CKD patients on dialysis typically have low or no additional out-of-pocket cost for IV iron specifically.

Non-dialysis CKD (Part B coverage): For non-dialysis patients, Venofer may be covered under Medicare Part B as a physician-office or outpatient infusion drug. No prior authorization is required under Part B. After the Part B deductible ($257 in 2025), Medicare pays 80% of the approved amount; the patient or Medigap plan pays 20%.

Billing tip: Use HCPCS code J1756 (injection, iron sucrose, 1 mg) correctly — code per milligram, not per vial. Current CMS policy allows billing for unused portions of single-dose vials (with JW modifier for discarded amounts), as long as vial waste is documented appropriately. Correct coding can improve facility reimbursement and reduce provider write-offs.

AR Assist: American Regent's Patient Assistance Program

American Regent offers the AR Assist Patient Assistance Program (PAP) for eligible patients who are uninsured or underinsured with demonstrated financial need. Through AR Assist, eligible patients may receive Venofer at no charge.

Provider role in PAP enrollment:

Applications are submitted by the provider (hospital, physician office, or infusion center) on behalf of the patient

Documentation required: confirmation of uninsured/underinsured status, proof of financial need, and a prescription from the provider

Contact: VenAccess Reimbursement Hotline at (877) 448-4766, M–F 9 AM–8 PM ET, or visit venofer.com

Designating a staff member to screen patients for PAP eligibility at intake and submit applications proactively can prevent treatment disruptions for your most vulnerable patients.

Optimizing Setting of Care to Reduce Patient Costs

Patient out-of-pocket costs for IV iron can vary significantly by setting. In general, physician office or dialysis center administration is more cost-effective for patients than hospital outpatient settings, which carry additional facility fees. If your patients have coverage for both settings, consider whether administering Venofer in your office rather than referring to a hospital infusion suite could reduce their coinsurance burden.

39,483+ patients found their medications in stock

39K+

Find Venofer In Stock Today →

Formulary Strategy: Generic Iron Sucrose

For practice managers and pharmacy directors, using FDA-approved generic iron sucrose as the default formulary choice for iron replacement is a straightforward cost reduction strategy. Generic iron sucrose is therapeutically equivalent to Venofer, carries the same clinical profile, and is typically less expensive than the brand. The savings to the facility can be meaningful, and there is no clinical disadvantage to patients. Many large dialysis chains already use generic iron sucrose as their standard.

Avoiding Unnecessary Escalation to Expensive IV Iron Products

When Venofer is available, it should be used in preference to more expensive IV iron products (Feraheme, Injectafer, Monoferric) for most CKD patients. Major payers including Aetna and UnitedHealthcare have step therapy policies that require Venofer or iron sucrose as the first-line IV iron before expensive alternatives are covered. Prescribing brand-name expensive alternatives without a documented shortage or clinical indication typically results in prior authorization denials and delays in patient care.

Skip the calls, skip the stress.

Find Venofer In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Third-Party Patient Assistance Resources

Prescription Hope: A national advocacy program that enrolls patients in manufacturer PAPs for a $70/month service fee. Useful for patients who qualify for the AR Assist PAP but need help navigating the application.

NeedyMeds.org: A database of patient assistance programs for medications. Free to search. Useful for helping patients identify all available cost assistance.

State pharmaceutical assistance programs: Several states offer supplemental drug assistance programs for low-income patients that may help cover the cost of IV medications.

How medfinder Supports Access

When patients face supply disruptions, the cost of traveling to distant facilities to receive treatment adds to their financial burden. medfinder's provider platform helps coordinate finding facilities with available stock, reducing patient transportation costs and treatment delays. Direct patients to our patient savings guide for a resource they can use independently.